Online inquiry

IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3207MR)

This product GTTS-WQ3207MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD70 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001252.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 970
UniProt ID P32970
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3207MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5908MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CIM 331
GTTS-WQ9928MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA KB-004
GTTS-WQ9737MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JR-141
GTTS-WQ654MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 8c10
GTTS-WQ12963MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PDL 192
GTTS-WQ14312MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RG-7221
GTTS-WQ3200MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ4845MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BT-062
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW